Current stock page

Financial Data

ZBIO Financial Data

Revenue · Earnings · Margins · Balance Sheet · Cash Flow

HealthcareBiotechnologyScore data as of Nov 13, 2026

ZBIOZenas BioPharma, Inc.

Healthcare / Biotechnology

Low Priority

In Line With Peers

BearishEdge 4/10
$28.01+$0.37 (+1.34%)

Latest quote

  • Momentum
    78
  • Value
    33
  • Quality
    25
  • Risk resilience
    39
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

Financial Data Overview

Detailed revenue, earnings, margins, balance sheet, cash flow, valuation metrics, technical indicators, and risk measures for deeper research.

Quarterly periods
8
Fundamental metrics
10
Technical indicators
12
Risk measures
6

Quarterly Financial Statements

Updated Nov 16, 2026.

Income statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Revenue$10M$1M$0$0$0$0$10M$5M
Gross Profit-$17.5M$1M-$6K-$55.72M-$5M-$43.03M$10M$5M
Operating Income-$103.41M-$107.66M-$77.35M-$237.98M-$52.58M-$55.16M-$37.33M-$55.62M
Net Income-$108.92M-$111.46M-$80.99M-$240.44M-$51.5M-$52.22M-$33.57M-$52.6M
EPS-$1.65-$1.77-$1.46-$5.17-$1.22-$1.25-$0.8-$1.26
Cash flow statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Operating Cash Flow-$57.98M-$57.24M-$75.2M-$52.41M-$41.13M-$41.74M-$37.05M-$38.55M
Capital Expenditure-$1K$0-$2K$0$0$0-$18K-$74K
Free Cash Flow-$57.99M-$57.24M-$75.2M-$52.41M-$41.13M-$41.74M-$37.07M-$38.63M
Net Cash Provided By Operating Activities-$57.98M-$57.24M-$75.2M-$52.41M-$41.13M-$41.74M-$37.05M-$38.55M
Balance sheet
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Total Assets$675.22M$701.69M$747.68M$383.64M$322.02M$293.09M$333.77M$369.97M
Total Debt$300.89M$389.6M$351.73M$79.96M$798K$1.01M$1.23M$1M
Cash And Cash Equivalents$177.78M$196.58M$500.22M$110.64M$115.57M$44.01M$196.55M$319.74M
Total Liabilities$462.91M$454.59M$411.85M$141.5M$125.59M$53.46M$49.45M$57.51M
Total Stockholders Equity$212.31M$247.1M$335.83M$242.14M$196.43M$239.63M$284.32M$312.46M
Key financial metrics
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio————————
P/B ratio8.87.463.34.467.682.78——
P/S ratio168.44———————
Debt To Equity1.421.581.050.330000
Free Cash Flow Yield-12.99%-12.26%-18.99%-15.96%-10.51%-22.31%——
Financial ratios
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio————————
P/B ratio8.87.463.34.467.682.78——
P/S ratio168.44———————
Return On Equity-255.20%-196.03%-126.60%-156.00%-96.68%-73.87%-57.25%-50.24%
Debt To Equity1.421.581.050.330000

Current Stock Metrics

Current fundamental, technical, and risk readings in one place.

Fundamental metrics
MetricValue
Pe-2.79x
Pb8.73x
EPS Growth Yoy-35.25%
Gross Margin-656.60%
Operating Margin-4785.47%
ROE-208.91%
ROIC-85.96%
Debt To Equity1.42
FCF Yield-12.78%

As of Nov 13, 2026

Technical indicators
MetricValue
Close$28.01
Volume304,828
RSI (14)50.08
MACD0.02
MACD signal-0.08
MACD histogram0.1
ADX (14)12.21
SMA (50)$28.58
SMA (200)$25.34
ATR (14)$1.77
Historical volatility (annualized)65.70%
Volume (20-day average)502,264

As of Nov 13, 2026

Risk measures
MetricValue
Resilience score39/100
Beta0.75
Annual volatility95.33%
Max Drawdown-64.79%
Sharpe Ratio0.26
VaR (95%, 1-day)-7.35%

As of Nov 13, 2026

Detailed Metrics

Additional measures remain available here while the decision pages stay focused.

Additional fundamental metrics

No additional fundamental metrics are available.

Additional technical indicators

No additional technical indicators are available.

Additional risk measures

No additional risk measures are available.

ZBIO Financial Data FAQ

What is Zenas BioPharma, Inc.'s revenue?

Zenas BioPharma, Inc.'s revenue is one of the core financial data points for ZBIO. Use it with revenue growth, margins, and EPS to understand whether sales are translating into earnings power.

Is Zenas BioPharma, Inc.'s revenue growing?

Revenue growth shows whether Zenas BioPharma, Inc. is expanding from prior periods. Compare growth with margins and free cash flow because faster sales growth is more valuable when profitability holds up.

What is ZBIO's EPS?

ZBIO's EPS, or earnings per share, helps connect net income to each share. EPS should be compared with EPS growth, P/E ratio, and analyst expectations.

What is Zenas BioPharma, Inc.'s net income?

Zenas BioPharma, Inc.'s net income shows profit after costs, taxes, and other expenses. It should be read with revenue, operating margin, EPS, and free cash flow.

How much free cash flow does Zenas BioPharma, Inc. generate?

Free cash flow shows how much cash Zenas BioPharma, Inc. generates after capital spending. It is useful for judging reinvestment capacity, buybacks, debt reduction, and valuation support.

How much cash and debt does Zenas BioPharma, Inc. have?

Cash and debt help frame ZBIO's balance-sheet flexibility. Compare liquidity and leverage with free cash flow and profitability before judging financial strength.